Kimura M
Department of Pharmacy, Kyoto University Hospital Faculty of Medicine, Japan.
Yakugaku Zasshi. 1992 Dec;112(12):914-8. doi: 10.1248/yakushi1947.112.12_914.
In order to elucidate the relationships between the antitumor activity and the molecular structure of novel acridine derivatives (1a-f, and 2a-e in Chart 1) the DNA-binding properties (intercalation) of the derivatives were examined by the quenching in fluorescence of an ethidium-DNA complex, which may be caused by the displacement of DNA-bound ethidium by a second DNA-binding ligand, acridines. The concentration (C50 value) of the acridine necessary to reduce the initial fluorescence of DNA-bound ethidium by 50% showed a good correlation with their antitumor activities. The fluorescence quenching of the acridines was examined using 4'-(9-acridinylamino)- methanesulfonanilide (amsacrine, AMSA) as a typical standard of the second DNA-bound ligand, and calf thymus DNA with an apparent site size of two base pairs.
为了阐明新型吖啶衍生物(图1中的1a - f和2a - e)的抗肿瘤活性与分子结构之间的关系,通过对溴化乙锭 - DNA复合物荧光淬灭来检测这些衍生物的DNA结合特性(嵌入作用),这可能是由于第二个DNA结合配体吖啶取代了与DNA结合的溴化乙锭所致。将与DNA结合的溴化乙锭初始荧光降低50%所需的吖啶浓度(C50值)与其抗肿瘤活性呈现出良好的相关性。使用4'-(9-吖啶基氨基)甲磺酰苯胺(安吖啶,AMSA)作为第二个与DNA结合配体的典型标准物,以及表观位点大小为两个碱基对的小牛胸腺DNA来检测吖啶的荧光淬灭情况。